Characterization of the common genetic variation in the Spanish population of Navarre

Authors:

Alberto Maillo, alberto.ruizdeinfante@kaust.edu.sa, Spain[1,2]

Estefania Huergo, ehuergoi@navarra.es, Spain[1,#]

María Apellániz-Ruiz, mv.apellaniz.ruiz@navarra.es, Spain[3,#]

Edurne Urrutia, eurrutil@navarra.es, Spain[1,3,#]

María Miranda, mmirandp@navarra.es, Spain[3]

Josefa Salgado, jsalgadg@navarra.es, Spain[3,4,5]

Sara Pasalodos-Sánchez, spasalos@navarra.es, Spain[3]

Luna Delgado-Mora, lunadelde@gmail.com, Spain[3,6]

Óscar Teijido, oteijidh@navarra.es, Spain[3]

Ibai Goicoechea, igoicoeo@nasertic.es, Spain[7]

Rosario Carmona, rosariom.carmona@juntadeandalucia.es, Spain[8,9,10,11]

Javier Perez-Florido, javier.perez.florido.sspa@juntadeandalucia.es, Spain[8,9,10,11]

Virginia Aquino, virginia.aquino@juntadeandalucia.es, Spain[8]

Daniel Lopez-Lopez, daniel.lopez.lopez@juntadeandalucia.es, Spain[8,9,11]

María Peña-Chilet, maria_pena@iislafe.es, Spain[8,11]

Sergi Beltrán, sergi.beltran@cnag.eu, Spain[12,13,14]

Joaquín Dopazo, joaquin.dopazo@juntadeandalucia.es, Spain[8,9,10,11]

Iñigo Lasa, ilasa@unavarra.es, Spain[15]

Juan José Beloqui, jj.beloqui.lizaso@navarra.es, Spain[3]

NAGEN-scheme (*see list at the end*)

Ángel Alonso, aalonsos@navarra.es, Spain[3*]

David Gomez-Cabrero, david.gomez.cabrero@navarra.es, Spain[1,2*]

Affiliations:

1: Translational Bioinformatics Unit, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), IdiSNA, Pamplona, Spain

2: Biological and Environmental Science and Engineering Division, King Abdullah University of Science and Technology (KAUST), Thuwal 23955-6900, Saudi Arabia.

3: Genomics Medicine Unit, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), IdiSNA, Pamplona, Spain

4: Servicio de Genética Médica-Hospital Universitario de Navarra (HUN), Pamplona, Spain.

5: Dp. Bioquímica y Biología Molecular-Universidad Pública de Navarra (UPNA), Pamplona, Spain.

6: Instituto de Genética Médica y Molecular (INGEMM), Hospital Universitario La Paz, Madrid, Spain.

7: Department of Personalized Medicine, NASERTIC, Government of Navarra, Pamplona, Spain.

8: Computational Medicine Platform, Andalusian Public Foundation Progress and Health-FPS, Sevilla, Spain.

9: Institute of Biomedicine of Seville, IBiS, University Hospital Virgen del Rocio/CSIC/University of Sevilla, Sevilla,
Spain.

10: FPS/ELIXIR-ES, Fundación Progreso y Salud (FPS), CDCA, Hospital Virgen del Rocio, Sevilla, Spain.

11: Biomedical Research Networking Center in Rare Diseases (CIBERER), Health Institute Carlos III, 28029 Madrid,
Spain.

12: CNAG-CRG, Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology,
Barcelona, Spain.

13: Universitat Pompeu Fabra (UPF), Barcelona, Spain.

14: Departament de Genètica, Microbiologia i Estadística, Facultat de Biologia, Universitat de Barcelona (UB),
Barcelona, Spain.

15: Laboratory of Microbial Pathogenesis, Navarrabiomed, Pamplona, Spain.

*corresponding: aalonsos@navarra.es and david.gomez.cabrero@navarra.es . [#]contributed equally

ABSTRACT

Large-scale genomic studies have significantly increased our knowledge of genetic variability

across populations. Regional genetic profiling is essential for distinguishing common benign

variants from disease-causing ones. To this end, we conducted a comprehensive characterization

of exonic variants in the population of Navarre (Spain), utilizing whole genome sequencing data

from 358 unrelated individuals of Spanish origin. Our analysis revealed 61,410 biallelic single

nucleotide variants (SNV) within the Navarrese cohort, with 35% classified as common (MAF >

1%). By comparing allele frequency data from 1000 Genome Project (excluding the Iberian cohort

of Spain, IBS), Genome Aggregation Database, and a Spanish cohort (including IBS individuals and

data from Medical Genome Project), we identified 1,069 SNVs common in Navarre but rare (MAF

≤ 1%) in all other populations. We further corroborated this observation with a second regional

cohort of 239 unrelated exomes, which confirmed 676 of the 1,069 SNVs as common in Navarre.

In conclusion, this study highlights the importance of population-specific characterization of

genetic variation to improve allele frequency filtering in sequencing data analysis to identify

disease-causing variants.

Keywords: personalized medicine, whole genome sequencing WGS, whole exome sequencing

WES, single nucleotide variant SNV, population frequencies, genetic variability.

 INTRODUCTION

In recent years, the use of NGS in patient healthcare has increased due to technological advances,

cost reduction, and enhanced efficiency.[1] The advancement of NGS spans a spectrum of

applications, encompassing whole exome/genome sequencing (WES/WGS). These technologies

revealed a wealth of genetic variants, necessitating the implementation of filters to narrow down

the list of candidate variants. In this regard, the availability of population-specific catalogues of

common variants enables the identification of rare variants,[2] such as the international initiatives

1000 Genome Project (1KGP)[3] and Genome Aggregation Database (gnomAD).[4] Moreover, various

countries like the UK,[5] USA,[6] and Japan[7] have established their databases. In Spain, for instance,

the Medical Genome Project (MGP) compiles data from unrelated healthy individuals.[89]

In Navarre, a 650,000 population region of north-eastern Spain, the local Government supported

the "*NAGEN scheme*" to integrate genomic data analysis into the regional public healthcare

system. Nowadays, NAGEN has generated numerous WES/WGS and associated phenoclinical

profiles in seven projects, including *NAGEN1000*, focused on rare diseases, and *pharmaNAGEN*

on pharmacogenomics in patients with inflammatory bowel diseases.[10] The NAGEN strategy's

success hinges on identifying population-specific common variants to establish a comprehensive

Navarrese population frequency catalogue.

In this study (Fig. 1), we aimed to identify and characterize common exonic variants specific to

the Navarrese population. Firstly, we identified common single nucleotide variants (SNVs) in

Navarre and rare in other populations. Secondly, we validated the allele frequency of these

variants in another Navarrese cohort with exome data. Finally, we annotated the resulting

variants using genomic databases, and their clinical and pharmacological effects and

pathogenicity were assessed. Additionally, we conducted functional enrichment analyses to

provide further insights. The results will significantly contribute to advancing personalized

medicine in Navarre.

MATERIAL AND METHODS

99

100   ***NAGEN1000* and *pharmaNAGEN***

101   In Navarre, the local Government supports the "*NAGEN scheme*", integrating genomic data

102   analysis into regional healthcare across seven projects. In the *NAGEN1000* project, 688

103   participants were recruited to uncover the underlying genetic causes of disease using WGS data.

104   These individuals belonged to 294 families, predominantly trios, affected by rare disorders.

105   Likewise, in the *pharmaNAGEN* project, 274 patients with Crohn's disease or ulcerative colitis

106   were recruited to analyze variants related to drug efficacy and toxicity on WES data.[10]

107

108   **Whole genome sequencing and data analysis**

109   High-quality DNA samples from peripheral blood were used in the *NAGEN1000* project to

110   construct short-insert paired-end libraries with an average insert size of 400 bp. DNA

111   fragmentation was performed with Covaris S2 and capillary electrophoresis with Bioanalyzer 2100

112   (Agilent). Libraries were sequenced on a NovaSeq 6000 (Illumina) with a read length of 2x150 bp.

113   A 30X coverage per sample was targeted. After quality control assessment using FASTQC

114   (https://www.bioinformatics.babraham.ac.uk/projects/fastqc/), the sequenced data was aligned

115   to hs37d5 version of human genome reference GRCh37/hg19 using GEM3.[11] Optical and

116   duplicated reads were flagged with Picard MarkDuplicates

117   (https://broadinstitute.github.io/picard/). Following the established Genome Analysis Toolkit

118   (GATK) best practices pipeline (v3.8),[12] indel realignments and recalibration were applied to the

119   previous BAM files. Variant calling on each sample's BAM file was performed using

120   HaplotypeCaller, with default parameters, resulting in a gVCF file. WGS was conducted at Centro

Nacional de Análisis Genómico (CNAG, Barcelona, Spain) and stored at Navarra de Servicios y

Tecnología (NASERTIC, Navarre, Spain).

Whole exome sequencing and data analysis

In the *pharmaNAGEN* project, germline DNA was extracted from saliva or blood samples using

DNA Blood Maxi Kit (Qiagen) and sequenced with Nextera DNA Exome kit. The raw data was

aligned to GRCh37/hg19 genome, sourced from UCSC (https://genome.ucsc.edu/), utilizing

BWA.[13]   The   resulting   BAM   files   were   marked   using   Picard

(https://broadinstitute.github.io/picard/). Utilizing GATK v4.1.0,[12] an updated version, eliminates

the need for the indel realignment step. Recalibration and variant calling were executed with

BQSR and Haplotype tools. This process yielded the final gVCF file for each sample. WES was

conducted at CNAG and stored at NASERTIC.

Individual selection

Selection criteria included unrelated individuals and Spanish ancestry. To assess relatedness

among individuals, identity-by-descent (IBD) was calculated using the method of moments

(MoM) with the R package SNPRelate.[14] For validation of ethnicity, the CSVS tool[9] was used to

determine the degree of alignment of a sample with the genetic variability of the Spanish

population. Individuals with a score equal to or higher than 0.9 were categorized as being of

Spanish ancestry.

Applying these selection criteria to the *NAGEN1000* project resulted in a cohort of 358

participants denominated NAVARREsel. Within this group, 127 individuals had been diagnosed

with various monogenic diseases, and the most prevalent conditions were polycystic kidney

disease (14/127), breast cancer (10/127), and hereditary ataxia (8/127).

Regarding the validation dataset, named NAVARREval, the same inclusion criteria were applied to

the *pharmaNAGEN* project, resulting in 239 participants with Crohn's disease (153/239) and/or

ulcerative colitis (86/239).

Variant quality control and filtering in NAVARREsel

A 358 multi-sample gVCF was generated with the NAVARREsel cohort, and biallelic SNVs located

in exonic regions were selected. The targeted exonic interval was extracted from Nextera

(https://support.illumina.com/sequencing/sequencing_kits/nextera-dna-

exome/downloads.html, downloaded on September 27, 2023). Variants with a read depth of less

than 10, a genotype-quality score below 50, or a call rate of less than 100% were removed.

Variants on the X and Y chromosomes were eliminated to avoid sex bias, as well as the

mitochondrial chromosome, given its complexity. Hardy-Weinberg equilibrium (HWE) score[15] was

calculated by PLINK (-hardy), and SNVs significantly deviated with p-value $< 10^{-5}$ were excluded.

Variant quality control and filtering in NAVARREval

Genotype information for specific SNVs from NAVARREval samples was extracted using the

SelectVariants tool of GATK v4.1.0.[12] SNVs with a call rate lower than 80% and those exhibiting a

significant deviation from HWE (p-value $< 10^{-5}$) were excluded from validation.

Variant annotation

Variants were annotated using ANNOVAR (version available on October 24th, 2019, https://annovar.openbioinformatics.org/).[16] The identification of known variants was performed using the dbSNP database (version GCF_000001405.25, downloaded from https://ftp.ncbi.nih.gov/snp/latest_release/VCF/).[17] SNVs were also annotated: 1) for clinical significance by referring to ClinVar (v.20230930, https://www.ncbi.nlm.nih.gov/clinvar/),[18] OMIM (downloaded on October 2, 2023, https://www.omim.org/),[19] VarSome,[20] and Franklin;[21] and 2) for pharmacological relevance using PharmGKB (https://www.pharmgkb.org/).[22] Additionally, the pathogenicity of the variants was evaluated using CADD (v1.6, https://cadd.gs.washington.edu/),[23] REVEL score (v1.3, https://zenodo.org/records/7072866),[24] spliceAI,[25] and Polyphen2 (http://genetics.bwh.harvard.edu/pph2/dokuwiki/downloads downloaded on October 4, 2023).[26] Variants associated with Crohn's disease and/or ulcerative colitis were identified by referencing the Inflammatory Bowel Disease (IBD) database (accessed on October 10, 2023, from https://www.cbrc.kaust.edu.sa/ibd/index.php?p=ibd#).[27]

Population projects

The MGP project was a Spanish initiative, primarily featuring WES data from 267 healthy and unrelated participants, mainly from Andalusia and Galicia (Spanish regions).[8]

The population data from 1KGP phase 3 encompassed 2,504 genome samples representing 26 populations.[28] European populations within this dataset included 503 samples from Europe (EUR), such as British in England and Scotland (GBR), Finnish in Finland (FIN), Iberian population in Spain (IBS), Toscani in Italy (TSI), and Utah residents with Northern and Western European

ancestry (CEU). Additionally, there were 504 samples from East Asia (EAS), 489 from South Asia

(SAS), 661 from Africa (AFR), and 347 from America (AMR), covering various populations.

The gnomAD genomes project v2.1.1 comprises 15,691 genomes and represents diverse

populations worldwide, including Africans, Americans, Asians, and Europeans. Within European

populations, the majority originated from North-western, Estonian, Finnish, and a smaller

representation from Southern Europe.[4]

Population frequencies

Based on the population projects described in the previous section, three populations were

generated for this study as reference: 1) gnomAD, with the original frequency from the gnomAD

genome project; 2) *1KGP_noIBS*, with the mean of all 1KGP population's frequencies, excluding

the IBS cohort of 107 individuals; 3) *spain*, combining the frequencies of the IBS and MGP cohorts.

The integration process for the *spain* population consisted of adding the number of total alternate

alleles divided by the sum of the total number of alleles across the two cohorts.

Principal Components Analysis, Admixture, and F_{ST} analysis

The original VCF files for each chromosome from the 1KGP phase3 were downloaded on

September 27, 2023, from https://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20130502/.

Subsequently, these files were merged using the Picard MergeVCFs tool. Access to the raw data

from MGP was granted upon request, and the multi-sample VCF was retrieved for the EGA

repository at https://ega-archive.org/datasets/EGAD00001003101. Then, the VCF files from

1KGP, MGP, and NAVARREsel were combined using the GATK tool's CombineGVCFs function. The

resulting combined file was used to perform Principal Component Analysis (PCA) with R libraries

SNPRelate and SNPassoc, conduct ADMIXTURE (v1.3.0)[29] from 3 to 7 genetic components (K), and

calculate the mean pairwise F_{ST} values between populations using vcftools (v0.1.17).[30]

Enrichment analysis

Functional enrichment, including pathway (KEGG), biological process (GO), disease (OMIM), and

human phenotype ontology (HPO), was performed using WebGestalt

(https://www.webgestalt.org/).[31]

RESULTS

Navarrese discovery cohort

The *NAGEN1000* WGS Navarrese project comprised 688 individuals from 294 families (mainly trios) with a rare disease. The WGS was conducted with a mean coverage of 30X, providing comprehensive genomic data across the entire genome. For our study, a subset of this cohort was selected satisfying two criteria: unrelatedness and Spanish ancestry. This result yielded 358 individuals, referred to as NAVARREsel.

Then, biallelic SNVs on chromosomes 1 to 22, from the exonic region covered by the Nextera Exome Enrichment kit, were extracted. Subsequently, variants with read depth < 10, genotype quality < 50, or missing genotype in at least one sample were filtered out. Additionally, sites significantly deviated from Hardy-Weinberg equilibrium (HWE, p-value < 10^{-5}) were removed.[32] Finally, 61,410 SNVs remained, of which 21,174 were identified as common variants (MAF > 1%). We observed that including additional individuals did not reveal new common variants, and 21,174 were achieved when considering over 100 individuals (Fig. S1a).

Genetic variation between Navarre, Spanish, and global populations

We performed a principal component analysis (PCA) on the shared variants between NAVARREsel, 1KGP, and MGP to depict its relationship. We observed a clear distinction between Navarre and Asian/African populations, reflecting established genetic differences (Fig. 2a). Conversely, an overlap is observed between Navarre and European populations, emphasizing their genetic affinity. Thus, focusing on European populations (Fig. 2b), we observed that Navarrese individuals are close to the Spanish populations (IBS and MGP) and exhibit proximity to Italian individuals

(TSI). This observation is supported when estimating the ancestries of the European populations

using ADMIXTURE.[29] The average number of ancestries in each population was calculated with

the optimal component K=3 (Fig. 2c). The Navarrese population showed the highest ancestral

proportion on component 1 at 61%, which started decreasing in the IBS and MGP populations to

30% and 20% respectively, and was nearly absent (0.1%) in Finland (FIN). In contrast, component

2 was predominant in the Finnish population (99%), while being the lowest in the Navarrese

cohort at 7%.

To further analyse the genetic differentiation, we calculated the mean pairwise F_{ST} values. The

lower F_{ST} value indicates greater similarity between populations. This occurred when comparing

Navarre with the Spanish ($F_{ST(Navarre-IBS)}$ = 0.0001 and $F_{ST(Navarre-MGP)}$ = 0.0007) and Italian ($F_{ST(Navarre-}$

$_{TSI)}$ = 0.0014) populations. In contrast, the highest differentiation was observed against East-Asian

and African populations ($F_{ST(Navarre-EAS)}$ = 0.0328, $F_{ST(Navarre-AFR)}$ = 0.0434, Table S1).

These findings, aligning with biological expectations, underscore the regional and continental

genetic affinities, providing insights into historical populations and evolutionary dynamics.

Exclusive common variants in Navarre

To identify exclusive Navarrese common variants, we examined allele frequency among Navarre

population and the three referenced populations: *1KGP_noIBS*, gnomAD, and *spain*. A

comparison of the MAF revealed that most variants (17,532 SNVs) were classified as common

(MAF > 1%) across the four populations. However, 835 variants exhibited higher prevalence solely

in Spanish cohorts (Navarre and *spain*). Specifically, 1,069 SNVs were identified as common in

Navarre, and rare (MAF ≤ 1%) in the rest (Fig. 3a).

To validate these 1,069 variants, we used the NAVARREval cohort, a subset of 239 WES unrelated

individuals of Spanish descent from the current Navarrese population and diagnosed with Crohn's

disease (159/239) or ulcerative colitis (86/239) (*pharmaNAGEN* project). Before validation, we

assessed the association of these SNVs with these conditions by cross-referencing them with

reported variants in the Inflammatory Bowel Disease database, which catalogues variants highly

linked to the mentioned diseases.[27] The absence of the 1,069 SNVs in this database ensured an

unbiased and robust validation process.

Among the 1,069 variants initially identified, 998 were detected in NAVARREval with a call rate

greater than 80% and demonstrated conformity to HWE. Notably, 676/998 of these SNVs (68%;

p-value = $2.2e^{-16}$) were consistently classified as common in NAVARREval, confirming their

prevalence within the Navarrese population (variants' information in Table S2). The validation

cohort was sufficient to validate the Navarrese common variants, reaching a plateau in Fig. S1b.

On the contrary, within the non-validated subset (322/998, 32%), 134 SNVs exhibited MAFs in

NAVARREsel that did not exceed a 2-fold difference in NAVARREval, indicating close MAF between

both datasets (Fig. S2). This exploration of MAF patterns ensures a comprehensive understanding

of the genetic landscape within the Navarre population and its stability across different datasets.

Characterization of common Navarrese variants

The annotation of the 676 common Navarrese SNVs revealed 227 synonymous, 371 missense,

and five loss-of-function (LoF) variants. These LoF variants were not reported in ClinVar

database[18] and were located in five distinct genes without an associated phenotype, according to

OMIM.[19] Following the ACMG guidelines for variant classification, four were classified as variants

of uncertain significance (VUS) and one as benign.[33]

Clinically, 264/676 SNVs were reported in ClinVar: 1/264 as a risk factor, 181/264 as benign/likely-

benign, 32/264 as VUS, 48/264 as having conflicting interpretations, and 2/264 as likely-

pathogenic. These likely-pathogenic missense variants were in *SCNN1B* [c.1688G>A p.Arg563Gln;

$MAF_{NAVARREsel}$=0.013, $MAF_{NAVARREval}$=0.016]   and   in   *PTGIS*   [c.824G>A   p.Arg275Gln;

$MAF_{NAVARREsel}$=0.013, $MAF_{NAVARREval}$=0.021], associated with "low renin hypertension" and

"childhood-onset schizophrenia" respectively, according to ClinVar.[18] The evidence supporting

these associations is limited, with a score of 1 out of 4 and reviewed by a single submitter record.

Therefore, given its notable prevalence in the Navarrese population, observed in healthy and

affected (not related to this phenotype) individuals, these variants might be reconsidered and

reclassified as VUS under the ACMG guidelines.[34]

In silico analysis of the 676 variants with functional predictors revealed eight variants as

pathogenic by three different pathogenicity tools (REVEL_score > 0.8,[24] CADD > 20,[23] and

Polyphen indicating "probably" or "possibly").[26] However, a comprehensive examination of

clinical databases, including ClinVar,[18] Varsome,[20] and Franklin,[21] contradicted these predictions

based on ACMG criteria. Instead, the majority of these variants were classified as uncertain

significance (1/8), likely benign (5/8), and benign (2/8). This suggests that these variants are not

disease-causing.

Additionally, the variant in *BPIFB3* [c.387-1G>T; $MAF_{NAVARREsel}$=0.01536, $MAF_{NAVARREval}$=0.02092],

predicted to impact the canonical splicing acceptor site (spliceAI score = 0.99), was reclassified as

benign based on the allele frequency and the number of homozygotes as per ACMG criteria,

indicating no clinical relevance.[25]

Moreover, common Navarrese variants showed no impact on drug metabolism/efficacy,

according to PharmGKB.[22] They did not exhibit significant enrichment in pathways, biological

processes, related diseases, or phenotypic ontologies.

Refining disease-causing variant identification in the Navarrese population

We identified common variants in the Navarrese population, highlighting population-specific

importance in advancing personalized medicine. The aim was to improve the identification of

disease-causing variants during genetic diagnosis using NGS. Therefore, we selected 127 WGS

Navarrese patients from *NAGEN1000* project diagnosed with rare disorders and extracted exonic

SNVs on chromosomes 1 to 22, averaging 8,871 variants per patient.

We refined the variant list by excluding common variants from *1KGP_noIBS*, gnomAD, *spain*, and

Navarre. The Navarrese filtering emerged as the most stringent, resulting in 2.1% of the initial set,

compared to 2.7% with gnomAD, 2.9% with *spain* frequencies, and the least restrictive, 4.9% with

1KGP_noIBS (Fig. 3). This underscores the effectiveness of Navarrese-specific filter in prioritizing

and streamlining genetic investigations.

DISCUSSION

In this study, we aimed to enhance diagnostic precision in the Navarrese population by exploring common population-specific variants. Utilizing WGS data from 358 individuals of Navarre, we identified 61,410 SNVs, with 21,174 common. Genetic analysis shows affinity with European populations and low differentiation with Spanish populations.

Focusing on exclusively common variants in Navarre compared with referenced populations, we obtained 1,069 SNVs, of which 676 were validated in another Navarrese cohort. Of these, none showed clinical or pharmacological relevance beyond what was observed in the Spanish population.[35] This aligns with the expectation that common population variants are less likely to be associated with disease ethology.

Our findings underscore the relevance of considering population-specific factors in genomic diagnostics, which provides complementary insights alongside pangenome references.[36] In conclusion, by identifying and excluding common variants within the Navarrese population, we have successfully refined the identification of potential disease-causing variants, contributing to the advancement of personalized medicine for individuals from Navarre. Further research will enhance these insights for broader applications.

DECLARATION OF INTEREST

Competing interests:

The authors declare no competing interests.

Ethics approval:

NAGEN1000 and *PharmaNAGEN* were approved by the Navarra Ethics Committee for Clinical Research (CEIC Navarra).

FUNDING

NAGEN1000 and *PharmaNAGEN* were supported by Navarra Gov (Dirección General de Industria, Energia y Proyectos Estrategicos S3). GRANTS_NUMBERS: 0011-1411-2017-000032, 0011-1411-2018-000047.

AUTHOR INFORMATION

Authors and Affiliations

Translational Bioinformatics Unit, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), IdiSNA, Pamplona, Spain

Alberto Maillo, Estefania Huergo, Edurne Urrutia & David Gomez-Cabrero

Biological and Environmental Science and Engineering Division, King Abdullah University of Science and Technology (KAUST), Thuwal 23955-6900, Saudi Arabia

Alberto Maillo & David Gomez-Cabrero

Genomics Medicine Unit, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), IdiSNA, Pamplona, Spain

María Apellániz-Ruiz, Edurne Urrutia, María Miranda, Josefa Salgado, Sara Pasalodos-Sánchez, Luna Delgado-Mora, Óscar Teijido, Juan José Beloqui & Ángel Alonso

Servicio de Genética Médica-Hospital Universitario de Navarra (HUN), Pamplona, Spain

Josefa Salgado

Dp. Bioquímica y Biología Molecular-Universidad Pública de Navarra (UPNA), Pamplona, Spain

Josefa Salgado

Instituto de Genética Médica y Molecular (INGEMM), Hospital Universitario La Paz, Madrid, Spain

Luna Delgado-Mora

Department of Personalized Medicine, NASERTIC, Government of Navarra, Pamplona, Spain.

Ibai Goicoechea

Computational Medicine Platform, Andalusian Public Foundation Progress and Health-FPS, Sevilla, Spain.

Rosario Carmona, Javier Perez-Florido, Virginia Aquino, Daniel Lopez-Lopez, María Peña-Chilet & Joaquín Dopazo

Institute of Biomedicine of Seville, IBiS, University Hospital Virgen del Rocio/CSIC/University of Sevilla, Sevilla, Spain.

Rosario Carmona, Javier Perez-Florido, Daniel Lopez-Lopez & Joaquín Dopazo

FPS/ELIXIR-ES, Fundación Progreso y Salud (FPS), CDCA, Hospital Virgen del Rocio, Sevilla, Spain.

Rosario Carmona, Javier Perez-Florido & Joaquín Dopazo

Biomedical Research Networking Center in Rare Diseases (CIBERER), Health Institute Carlos III, 28029 Madrid, Spain

Rosario Carmona, Javier Perez-Florido, Daniel Lopez-Lopez, María Peña-Chilet & Joaquín Dopazo

CNAG-CRG, Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and
Technology, Barcelona, Spain
Sergi Beltrán

Universitat Pompeu Fabra (UPF), Barcelona, Spain
Sergi Beltrán

Departament de Genètica, Microbiologia i Estadística, Facultat de Biologia, Universitat de
Barcelona (UB), Barcelona, Spain
Sergi Beltrán

Laboratory of Microbial Pathogenesis, Navarrabiomed, Pamplona, Spain
Iñigo Lasa
394

Contributions

Conceptualisation (AM, AA, DGC); Clinical and sample collection: (MM, LDM, OT, JS, MAR, SPS);

Formal analysis (AM, RC, JPF, VA, DLL, MPC); Data curation (AM); Investigation (AM, EH, MAR,

EU, DGC); Funding acquisition (JB, AA); Visualisation (AM, EH, MAR, EU); Writing-original draft

(AM, EH, MAR, EU, DGC) Writing-review & editing (AM, MAR, EH, EU, SB, SPS, IG, JD, IL, JB, AA,

DGC).

Corresponding authors

Correspondence to Ángel Alonso & David Gomez-Cabrero (david.gomez.cabrero@navarra.es).

NAGEN scheme

Name	Department	NAGEN project
Anda Apiñaniz, Emma	Servicio de Endocrinología y Nutrición, HUN	NAGEN 1,000

Artigas López, Mercedes	Servicio de Genética Médica, HUN	NAGEN 1,000
Bandrés Elizalde, Eva	Servicio de Hematología, HUN	NAGEN 1,000
Basurte Elorz, Mª Teresa	Servicio de Cardiología, CHN	NAGEN 1,000
Brennan, Paul	NENC NHS Genomic Medicine Centre. Newcastle upon Tyne, UK.	NAGEN 1,000
Celaya Lecea, Concepción	Subdirección de Farmacia, SNS-O	PharmaNAGEN
Cuesta Zorita, Manuel Jesús	Servicio de Psiquiatría, Salud mental	NAGEN 1,000
Curi Chercoles, Sergio Miguel	Servicio de Neumología, HUN	NAGEN 1,000
De la Cruz Sánchez, Susana	Servicio de Oncología Médica, HUN	NAGEN 1,000
Erviti López, Juan	Subdirección de Farmacia, SNS-O	PharmaNAGEN
Fanlo Mateo, Patricia	Servicio de Medicina Interna, HUN	NAGEN 1,000
González, Luis Angel	AVANTIA 400+.	NAGEN 1,000
Gonzalo Etayo	Navarra de Servicios y Tecnología NASERTIC. Spain	NAGEN 1,000
Gorricho Mendívil, Javier	Subdirección de Farmacia, SNS-O	PharmaNAGEN

Guerra Lacunza, Ana	Servicio de Aparato Digestivo, HUN	NAGEN 1,000
Gut, Ivo	Centro Nacional de Análisis Genómicos CNAG. Spain	NAGEN 1,000
Ibáñez Bosch, Rosario	Servicio de Endocrinología y Nutrición, HUN	NAGEN 1,000
Jiménez, Jorge	Navarra de Servicios y Tecnología NASERTIC. Spain	NAGEN 1,000
Lasheras, Gorka	Navarra de Servicios y Tecnología NASERTIC. Spain	NAGEN 1,000
Lorea Bueno	Pharmamodelling	PharmaNAGEN
Maite Sarobe Carricas	Servicio de Farmacia Hospitalaria, HUN	PharmaNAGEN
Mendioroz Iriarte, Maite	Servicio de Neurología, HUN	NAGEN 1,000
Molinuevo Ruiz de Zarate, José Ignacio	Servicio de Oftalmología, HUN	NAGEN 1,000
Montes Díaz, Marta	Servicio de Anatomía Patológica, HUN	NAGEN 1,000
Navarro, Adela	Servicio de Cardiología, HUN	PharmaNAGEN
Onintza Sayar	Pharmamodelling	PharmaNAGEN
Pinillos, Iñaki	Navarra de Servicios y Tecnología NASERTIC. Spain	NAGEN 1,000

Purroy Irurzon, Carolina Eugenia	Servicio de Nefrología, HUN	NAGEN 1,000
Sagaseta de Ilurdoz Uranga, Mª Josefa	Servicio de Pediatría, HUN	NAGEN 1,000
Santesteban Muruzabal, Raquel	Servicio de Dermatología, HUN	NAGEN 1,000
Vicuña, Miren	Servicio de Digestivo, HUN	PharmaNAGEN
Viguria, Mª Cruz	Servicio de Hematología, HUN	PharmaNAGEN
Yoldi Petri, Mª Eugenia	Servicio de Pediatría, HUN	NAGEN 1,000
Zubicaray Ugarteche, José Jacinto	Servicio de Otorrinolaringología, HUN	NAGEN 1,000
Zudaire, Maite	Servicio de Hematología, HUN	PharmaNAGEN

DATA AND CODE AVAILABILITY

Data is available from the corresponding author upon reasonable request.

REFERENCES

1. Satam H, Joshi K, Mangrolia U, et al. Next-Generation Sequencing Technology: Current Trends and Advancements. *Biology (Basel)*. 2023;12(7):997. doi:10.3390/biology12070997

2. Fattahi Z, Beheshtian M, Mohseni M, et al. Iranome: A catalog of genomic variations in the Iranian population. *Hum Mutat*. 2019;40(11):1968-1984. doi:10.1002/humu.23880

3. 1000 Genomes Project Consortium, Abecasis GR, Altshuler D, et al. A map of human genome variation from population-scale sequencing. *Nature*. 2010;467(7319):1061-1073. doi:10.1038/nature09534

4. Gudmundsson S, Singer-Berk M, Watts NA, et al. Variant interpretation using population databases: Lessons from gnomAD. *Hum Mutat*. 2022;43(8):1012-1030. doi:10.1002/humu.24309

5. Smetana J, Brož P. National Genome Initiatives in Europe and the United Kingdom in the Era of Whole-Genome Sequencing: A Comprehensive Review. *Genes (Basel)*. 2022;13(3):556. doi:10.3390/genes13030556

6. Ramirez AH, Sulieman L, Schlueter DJ, et al. The All of Us Research Program: Data quality, utility, and diversity. *Patterns*. 2022;3(8):100570. doi:10.1016/j.patter.2022.100570

7. Mitsuhashi N, Toyo-oka L, Katayama T, et al. TogoVar: A comprehensive Japanese genetic variation database. *Hum Genome Var*. 2022;9(1):44. doi:10.1038/s41439-022-00222-9

8. Dopazo J, Amadoz A, Bleda M, et al. 267 Spanish Exomes Reveal Population-Specific Differences in Disease-Related Genetic Variation. *Mol Biol Evol*. 2016;33(5):1205-1218. doi:10.1093/molbev/msw005

9.   Peña-Chilet M, Roldán G, Perez-Florido J, et al. CSVS, a crowdsourcing database of the

Spanish population genetic variability. *Nucleic Acids Res*. 2021;49(D1):D1130-D1137.

doi:10.1093/nar/gkaa794

10.   NAGEN | Navarrabiomed. Accessed November 28, 2023.

https://www.navarrabiomed.es/en/nagen

11.   Marco-Sola S, Sammeth M, Guigó R, Ribeca P. The GEM mapper: fast, accurate and

versatile alignment by filtration. *Nat Methods*. 2012;9(12):1185-1188.

doi:10.1038/nmeth.2221

12.   McKenna A, Hanna M, Banks E, et al. The Genome Analysis Toolkit: a MapReduce

framework for analyzing next-generation DNA sequencing data. *Genome Res*.

2010;20(9):1297-1303. doi:10.1101/gr.107524.110

13.   Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform.

Bioinformatics. 2009;25(14):1754-1760. doi:10.1093/bioinformatics/btp324

14.   Zheng X, Levine D, Shen J, Gogarten SM, Laurie C, Weir BS. A high-performance

computing toolset for relatedness and principal component analysis of SNP data.

Bioinformatics. 2012;28(24):3326-3328. doi:10.1093/bioinformatics/bts606

15.   Wigginton JE, Cutler DJ, Abecasis GR. A Note on Exact Tests of Hardy-Weinberg

Equilibrium. *The American Journal of Human Genetics*. 2005;76(5):887-893.

doi:10.1086/429864

16.   Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from

high-throughput sequencing data. *Nucleic Acids Res*. 2010;38(16):e164-e164.

doi:10.1093/nar/gkq603

17.   Sherry ST. dbSNP: the NCBI database of genetic variation. *Nucleic Acids Res*.

453   2001;29(1):308-311. doi:10.1093/nar/29.1.308

454   18.   Landrum MJ, Lee JM, Riley GR, et al. ClinVar: public archive of relationships among

455   sequence variation and human phenotype. *Nucleic Acids Res*. 2014;42(Database

456   issue):D980-5. doi:10.1093/nar/gkt1113

457   19.   Amberger J, Bocchini CA, Scott AF, Hamosh A. McKusick's Online Mendelian Inheritance in

458   Man (OMIM(R)). *Nucleic Acids Res*. 2009;37(Database):D793-D796.

459   doi:10.1093/nar/gkn665

460   20.   Kopanos C, Tsiolkas V, Kouris A, et al. VarSome: the human genomic variant search

461   engine. *Bioinformatics*. 2019;35(11):1978-1980. doi:10.1093/bioinformatics/bty897

462   21.   Franklin. Accessed November 28, 2023. https://franklin.genoox.com/clinical-db/home

463   22.   Thorn CF, Klein TE, Altman RB. PharmGKB: The Pharmacogenomics Knowledge Base. In: ;

464   2013:311-320. doi:10.1007/978-1-62703-435-7_20

465   23.   Rentzsch P, Witten D, Cooper GM, Shendure J, Kircher M. CADD: predicting the

466   deleteriousness of variants throughout the human genome. *Nucleic Acids Res*.

467   2019;47(D1):D886-D894. doi:10.1093/nar/gky1016

468   24.   Ioannidis NM, Rothstein JH, Pejaver V, et al. REVEL: An Ensemble Method for Predicting

469   the Pathogenicity of Rare Missense Variants. *The American Journal of Human Genetics*.

470   2016;99(4):877-885. doi:10.1016/j.ajhg.2016.08.016

471   25.   Jaganathan K, Kyriazopoulou Panagiotopoulou S, McRae JF, et al. Predicting Splicing from

472   Primary Sequence with Deep Learning. *Cell*. 2019;176(3):535-548.e24.

473   doi:10.1016/j.cell.2018.12.015

26.   Adzhubei I, Jordan DM, Sunyaev SR. Predicting Functional Effect of Human Missense

Mutations Using PolyPhen-2. *Curr Protoc Hum Genet*. 2013;76(1).

doi:10.1002/0471142905.hg0720s76

27.   Khan F, Radovanovic A, Gojobori T, Kaur M. IBDDB: a manually curated and text-mining-

enhanced database of genes involved in inflammatory bowel disease. *Database*.

2021;2021. doi:10.1093/database/baab022

28.   Auton A, Abecasis GR, Altshuler DM, et al. A global reference for human genetic variation.

Nature. 2015;526(7571):68-74. doi:10.1038/nature15393

29.   Patterson N, Moorjani P, Luo Y, et al. Ancient Admixture in Human History. *Genetics*.

2012;192(3):1065-1093. doi:10.1534/genetics.112.145037

30.   Danecek P, Auton A, Abecasis G, et al. The variant call format and VCFtools.

Bioinformatics. 2011;27(15):2156-2158. doi:10.1093/bioinformatics/btr330

31.   Wang J, Vasaikar S, Shi Z, Greer M, Zhang B. WebGestalt 2017: a more comprehensive,

powerful, flexible and interactive gene set enrichment analysis toolkit. *Nucleic Acids Res*.

2017;45(W1):W130-W137. doi:10.1093/nar/gkx356

32.   Anderson CA, Pettersson FH, Clarke GM, Cardon LR, Morris AP, Zondervan KT. Data quality

control in genetic case-control association studies. *Nat Protoc*. 2010;5(9):1564-1573.

doi:10.1038/nprot.2010.116

33.   Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of

sequence variants: a joint consensus recommendation of the American College of

Medical Genetics and Genomics and the Association for Molecular Pathology. *Genetics in*

Medicine. 2015;17(5):405-424. doi:10.1038/gim.2015.30

34. Li Q, Wang K. InterVar: Clinical Interpretation of Genetic Variants by the 2015 ACMG-AMP

Guidelines. *The American Journal of Human Genetics*. 2017;100(2):267-280.

doi:10.1016/j.ajhg.2017.01.004

35. Nunez-Torres R, Pita G, Peña-Chilet M, et al. A Comprehensive Analysis of 21 Actionable

Pharmacogenes in the Spanish Population: From Genetic Characterisation to Clinical

Impact. *Pharmaceutics*. 2023;15(4):1286. doi:10.3390/pharmaceutics15041286

36. Liao WW, Asri M, Ebler J, et al. A draft human pangenome reference. *Nature*.

2023;617(7960):312-324. doi:10.1038/s41586-023-05896-x

FIGURES LEGENDS

Figure 1: Workflow of this study. Abbreviations: *MGP*, Medical Genome Project; *1KGP*, 1000 Genomes Project; *1KGP_noIBS*, 1000 Genomes Project without Iberian population; *gnomAD,* Genome Aggregation Database; *MAF*, minor allele frequency; *SNV*, single nucleotide variant; *SNP*, single nucleotide polymorphism; *WGS*, whole genome sequencing; *WES*, whole exome sequencing; *LoF*, Loss-of-function; HPO, Human Phenotype Ontology; BP, biological process.

Figure 2: a) Principal component analysis of overlapped variants between NAVARREsel, MGP, and 1KGP (including all populations), and coloured by superpopulations. **b)** Principal component analysis of overlapped variants between NAVARREsel, MGP, and 1KGP (including exclusively European populations). **c)** Genetic admixture analysis of 1,128 individuals from 7 European populations for the optimal *K* value = 3. Abbreviations: PCA, principal component analysis; AFR, African populations; AMR, American populations; EAS, east-Asian populations; SAS, south-Asian populations; EUR, European populations; IBS, Iberian populations in Spain; MGP, Medical Genome Project; TSI, Toscani in Italy; CEU, Utah residents with Northern and Western European ancestry; GBR, British in England and Scotland; FIN, Finnish in Finland.

Figure 3: a) Upset plot of common variants (MAF > 1%) of each population: NAVARREsel, *spain*, *1KGP_noIBS*, and gnomAD **b)** Resulting percentage of variants per patient (n=127) after removing common variants from Navarre, *spain*, gnomAD, or *1KGP_noIBS* populations. The box plots represent the median, upper, and lower quartiles by the centre line and box bounds, respectively. Whiskers display the largest and smallest values within 1.5 times the interquartile range from the quartiles. Abbreviations: *1KGP_noIBS*, 1000 Genomes Project without Iberian population; gnomAD, Genome Aggregation Database; *spain*, integration of IBS and MGP populations.